We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
LabCorp Forms Lab-Alliance With Kentucky-Based Health Firm
Read MoreHide Full Article
Over the last few days, Laboratory Corporation of Americas Holdings (LH - Free Report) (popularly known as LabCorp) has been dominating headlines on several strategic developments. Following its extended alliance with Interpace Diagnostics (IDXG - Free Report) announced earlier this week, LabCorp has formed of one more joint venture — this time with Appalachian Regional Healthcare.
This multi-year, comprehensive laboratory collaboration will help LabCorp provide high-quality, high-value and standardized laboratory diagnostics to Appalachian Regional Healthcare’s hospital-based labs. Apart from technical services, LabCorp will aid in reference testing for Appalachian Regional Healthcare’s entire network of facilities and clinicians plus make enhanced information technology and data analytics accessible to help improve the delivery of patient care.
This alliance is expected to strengthen LabCorp’s diagnostic testing foothold in Eastern Kentucky and Southern West Virginia.
Progress on Strategic Collaborations
We note that LabCorp has fortified its footprint in the diagnostics space through both organic and inorganic means plus plans to collaborate with the leading companies and academic institutions to build a wider portfolio of tests.
The company continues to increase its scale and competencies in clinical laboratory medicine via acquisitions ranging from routine capabilities to highly esoteric testing. Among its recent alliances, under the new agreement with Interpace Diagnostics, Dianon Pathology — a member of the LabCorp Specialty Testing Group — will perform the thyroid biopsy analysis.
This apart, worth mentioning are the company’s two major health systems partnerships, Mount Sinai Health System and PAML, a market-leading reference and outreach laboratory based in Pacific Northwest. Per LabCorp, these anchor health systems will gradually emerge as research hubs, improving access to trials as well as Covance's site activation and investigator, and patient recruitment capabilities.
Other recent collaborations include a strategic partnership with Thermo Fisher (TMO - Free Report) , through which, the Thermo Fisher Oncomine Dx target panel was launched for non-small cell lung cancer patients. Also, riding on its partnership with drug retailer Walgreens (WBA - Free Report) , the company works on developing and operating patient service centers within select Walgreens stores. Besides these, significant is its tie-up with Japan-based Sysmex Corporation, a foremost clinical laboratory services provider and Roche, the world's reputed biotech company.
Share Price Performance
Over the past three months, shares of LabCorp have outperformed its industry. The stock has gained 3.1% against the industry’s 0.1% decline.
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
LabCorp Forms Lab-Alliance With Kentucky-Based Health Firm
Over the last few days, Laboratory Corporation of Americas Holdings (LH - Free Report) (popularly known as LabCorp) has been dominating headlines on several strategic developments. Following its extended alliance with Interpace Diagnostics (IDXG - Free Report) announced earlier this week, LabCorp has formed of one more joint venture — this time with Appalachian Regional Healthcare.
This multi-year, comprehensive laboratory collaboration will help LabCorp provide high-quality, high-value and standardized laboratory diagnostics to Appalachian Regional Healthcare’s hospital-based labs. Apart from technical services, LabCorp will aid in reference testing for Appalachian Regional Healthcare’s entire network of facilities and clinicians plus make enhanced information technology and data analytics accessible to help improve the delivery of patient care.
This alliance is expected to strengthen LabCorp’s diagnostic testing foothold in Eastern Kentucky and Southern West Virginia.
Progress on Strategic Collaborations
We note that LabCorp has fortified its footprint in the diagnostics space through both organic and inorganic means plus plans to collaborate with the leading companies and academic institutions to build a wider portfolio of tests.
The company continues to increase its scale and competencies in clinical laboratory medicine via acquisitions ranging from routine capabilities to highly esoteric testing. Among its recent alliances, under the new agreement with Interpace Diagnostics, Dianon Pathology — a member of the LabCorp Specialty Testing Group — will perform the thyroid biopsy analysis.
This apart, worth mentioning are the company’s two major health systems partnerships, Mount Sinai Health System and PAML, a market-leading reference and outreach laboratory based in Pacific Northwest. Per LabCorp, these anchor health systems will gradually emerge as research hubs, improving access to trials as well as Covance's site activation and investigator, and patient recruitment capabilities.
Other recent collaborations include a strategic partnership with Thermo Fisher (TMO - Free Report) , through which, the Thermo Fisher Oncomine Dx target panel was launched for non-small cell lung cancer patients. Also, riding on its partnership with drug retailer Walgreens (WBA - Free Report) , the company works on developing and operating patient service centers within select Walgreens stores. Besides these, significant is its tie-up with Japan-based Sysmex Corporation, a foremost clinical laboratory services provider and Roche, the world's reputed biotech company.
Share Price Performance
Over the past three months, shares of LabCorp have outperformed its industry. The stock has gained 3.1% against the industry’s 0.1% decline.
LabCorp carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>